Follow
Fernando Marin
Fernando Marin
Department of Endocrinology. Hospital Universitario Quironsalud. Madrid. Spain
Verified email at quironsalud.es
Title
Cited by
Cited by
Year
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
KG Saag, E Shane, S Boonen, F Marín, DW Donley, KA Taylor, GP Dalsky, ...
New England Journal of Medicine 357 (20), 2028-2039, 2007
10672007
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised …
DL Kendler, F Marin, CAF Zerbini, LA Russo, SL Greenspan, V Zikan, ...
The Lancet 391 (10117), 230-240, 2018
5012018
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
BM Obermayer‐Pietsch, F Marin, EV McCloskey, P Hadji, J Farrerons, ...
Journal of bone and mineral research 23 (10), 1591-1600, 2008
3022008
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
S Boonen, F Marin, B Obermayer-Pietsch, ME Simoes, C Barker, ...
The Journal of Clinical Endocrinology & Metabolism 93 (3), 852-860, 2008
2582008
Change in bone density and reduction in fracture risk: a meta‐regression of published trials
ML Bouxsein, R Eastell, LY Lui, LA Wu, AE de Papp, A Grauer, F Marin, ...
Journal of Bone and Mineral Research 34 (4), 632-642, 2019
2452019
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)
R Eastell, T Nickelsen, F Marin, C Barker, P Hadji, J Farrerons, M Audran, ...
Journal of bone and mineral research 24 (4), 726-736, 2009
2232009
Relationship between bone quantitative ultrasound and fractures: A meta‐analysis
F Marín, J González‐Macías, A Díez‐Pérez, S Palma, ...
Journal of bone and mineral research 21 (7), 1126-1135, 2006
2072006
Teriparatide for osteoporosis: importance of the full course
R Lindsay, JH Krege, F Marin, L Jin, JJ Stepan
Osteoporosis international 27, 2395-2410, 2016
1992016
Comparative effects of teriparatide and risedronate in glucocorticoid‐induced osteoporosis in men: 18‐month results of the EuroGIOPs trial
CC Glüer, F Marin, JD Ringe, F Hawkins, R Möricke, N Papaioannu, ...
Journal of bone and mineral research 28 (6), 1355-1368, 2013
1872013
Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis
RR Recker, F Marin, S Ish‐Shalom, R Möricke, F Hawkins, G Kapetanos, ...
Journal of Bone and Mineral Research 24 (8), 1358-1368, 2009
1792009
Monitoring teriparatide‐associated changes in vertebral microstructure by high‐resolution CT in vivo: results from the EUROFORS study
C Graeff, W Timm, TN Nickelsen, J Farrerons, F Marín, C Barker, CC Glüer
Journal of Bone and Mineral Research 22 (9), 1426-1433, 2007
1712007
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective
S Boonen, F Marin, D Mellstrom, L Xie, D Desaiah, JH Krege, CJ Rosen
Journal of the American Geriatrics Society 54 (5), 782-789, 2006
1552006
Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort
J González-Macías, F Marin, J Vila, A Díez-Pérez
Bone 50 (1), 373-377, 2012
1502012
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status
BL Langdahl, F Marin, E Shane, H Dobnig, JR Zanchetta, M Maricic, ...
Osteoporosis International 20, 2095-2104, 2009
1472009
High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA …
C Graeff, F Marin, H Petto, O Kayser, A Reisinger, J Peña, P Zysset, ...
Bone 52 (2), 568-577, 2013
1442013
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized …
C Turbí, G Herrero-Beaumont, JC Acebes, A Torrijos, J Graña, R Miguélez, ...
Clinical therapeutics 26 (2), 245-256, 2004
1302004
Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results …
J Borggrefe, C Graeff, TN Nickelsen, F Marin, CC Glüer
Journal of Bone and Mineral Research 25 (3), 472-481, 2010
1252010
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple …
DM Black, DC Bauer, E Vittinghoff, LY Lui, A Grauer, F Marin, S Khosla, ...
The lancet Diabetes & endocrinology 8 (8), 672-682, 2020
1202020
Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational …
BL Langdahl, G Rajzbaum, F Jakob, D Karras, Ö Ljunggren, WF Lems, ...
Calcified tissue international 85, 484-493, 2009
1202009
Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound
A Diez-Perez, J Gonzalez-Macias, F Marin, M Abizanda, R Alvarez, ...
Osteoporosis International 18, 629-639, 2007
1082007
The system can't perform the operation now. Try again later.
Articles 1–20